BCRX
BioCryst Pharmaceuticals Inc
NASDAQ: BCRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$8.37
+3.33% today
Updated 2026-10-28
Market cap
$1.99B
P/E ratio
—
P/S ratio
2.12x
EPS (TTM)
$-1.40
Dividend yield
—
52W range
$6 – $11
Volume
4.8M
BioCryst Pharmaceuticals Inc (BCRX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$8.37
12-Month target
$9.40
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.2B | $0.3B | $0.3B | $0.5B | $0.9B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -40.90%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.